Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

NCT01929031
View directory record Official record
Conditions
Pain, Postoperative, Tooth Diseases
Interventions
ibuprofen + caffeine, ibuprofen, caffeine, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

NCT00002194
View directory record Official record
Conditions
HIV Infections
Interventions
Erythromycin, Nevirapine, Clarithromycin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

NCT01397162
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate, Placebo, BI 54903
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

NCT03835481
View directory record Official record
Conditions
Psoriasis
Interventions
BI 730357, Placebo to match BI 730357
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 4, 2026, 6:42 PM EDT
Not listed No phase listed Observational

Advancing the Patient Experience in Chronic Obstructive Pulmonary Disease (APEX COPD)

NCT04285047
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (13645005)
Interventions
Advancing Patient Experience (APEX) in COPD
Other
Lead sponsor
Optimum Patient Care
Other
Eligibility
35 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Fort Collins, Colorado • Buffalo, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06006585
View directory record Official record
Conditions
Geographic Atrophy
Interventions
BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Phase 1 Interventional Results available

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT02003573
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
decitabine iv, volasertib iv infusion
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 4, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
Interventions
Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Cerritos, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401
View directory record Official record
Conditions
Early Parkinson Disease (Early PD)
Interventions
Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

NCT04822701
View directory record Official record
Conditions
COVID-19
Interventions
BI 767551 intravenous, BI 767551 inhaled, Placebo intravenous, Placebo inhaled
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Miami Springs, Florida • Amarillo, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 4, 2026, 6:42 PM EDT
Not listed No phase listed Observational

Safety of Oral Anticoagulants Registry

NCT02745054
View directory record Official record
Conditions
Blood Coagulation
Interventions
mgt of bleeding concerns/complications of oral anticoagulants
Other
Lead sponsor
Hospital Quality Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 4, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

NCT06619405
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Streetlab VR
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
50 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 4, 2026, 6:42 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370
View directory record Official record
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
88
States / cities
Beverly Hills, California • Covina, California • Encinitas, California + 74 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

NCT00860262
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine, telmisartan, telmisartan and amlodipine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
30
States / cities
Buena Park, California • Long Beach, California • Roseville, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 4, 2026, 6:42 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

NCT05846516
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
VSV-GP154, ATP150, ATP152, Ezabenlimab, ATP162
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Lamivudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 4, 2026, 6:42 PM EDT
Not listed Not applicable Interventional

Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

NCT04862858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Educational Intervention
Other
Lead sponsor
Humana Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
4,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 4, 2026, 6:42 PM EDT
Completed No phase listed Observational Results available

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

NCT03238963
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 4, 2026, 6:42 PM EDT